NCT07177508View on ClinicalTrials.gov

First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory

CompletedOBSERVATIONAL
Enrollment

2,355

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions
Respiratory Syncytial Viral (RSV) InfectionRespiratory Syncytial Virus HospitalizationsRespiratory Syncytial Virus Prevention
Trial Locations (1)

2605

The Canberra Hospital, Garran

All Listed Sponsors
lead

Nicola Irwin

OTHER

NCT07177508 - First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory | Biotech Hunter | Biotech Hunter